Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation

Authors: Wen-Shan Liu, Chung-Han Hsin, Ying-Hsiang Chou, Jung-Tung Liu, Ming-Fang Wu, Szu-Wen Tseng, Jong-Kang Lee, Hsien-Chun Tseng, Tzu-Hwei Wang, Mao-Chang Su, Huei Lee

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

The objective of this retrospective study is to investigate laryngeal preservation and long-term treatment results in hypopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) combined with chemotherapy.

Methods

Twenty-seven patients with hypopharyngeal carcinoma (stage II-IV) were enrolled and underwent concurrent chemoradiotherapy. The chemotherapy regimens were monthly cisplatin and 5-fluorouracil for six patients and weekly cisplatin for 19 patients. All patients were treated with IMRT with simultaneous integrated boost technique. Acute and late toxicities were recorded based on CTCAE 3.0 (Common Terminology Criteria for Adverse Events).

Results

The median follow-up time for survivors was 53.0 months (range 36-82 months). The initial complete response rate was 85.2%, with a laryngeal preservation rate of 63.0%. The 5-year functional laryngeal, local-regional control, disease-free and overall survival rates were 59.7%, 63.3%, 51.0% and 34.8%, respectively. The most common greater than or equal to grade 3 acute and late effects were dysphagia (63.0%, 17 of 27 patients) and laryngeal stricture (18.5%, 5 of 27 patients), respectively. Patients belonging to the high risk group showed significantly higher risk of tracheostomy compared to the low risk group (p = 0.014).

Conclusions

After long-term follow-up, our results confirmed that patients with hypopharyngeal carcinoma treated with IMRT concurrent with platinum-based chemotherapy attain high functional laryngeal and local-regional control survival rates. However, the late effect of laryngeal stricture remains a problem, particularly for high risk group patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference MacKenzie RG, Franssen E, Balogh JM, Gilbert RW, Birt D, Davidson J: Comparing treatment outcomes of radiotherapy and surgery in locally advanced carcinoma of the larynx: A comparison limited to patients eligible for surgery. Int J Radiat Oncol Biol Phys. 2000, 47: 65-71.CrossRefPubMed MacKenzie RG, Franssen E, Balogh JM, Gilbert RW, Birt D, Davidson J: Comparing treatment outcomes of radiotherapy and surgery in locally advanced carcinoma of the larynx: A comparison limited to patients eligible for surgery. Int J Radiat Oncol Biol Phys. 2000, 47: 65-71.CrossRefPubMed
2.
go back to reference Mendenhall WM, Million RR, Sharkey DE, Cassisi NJ: Stage T3 squamous cell carcinoma of the glottic larynx treated with surgery and/or radiation therapy. Int J Radiat Oncol Biol Phys. 1984, 18: 24-35. Mendenhall WM, Million RR, Sharkey DE, Cassisi NJ: Stage T3 squamous cell carcinoma of the glottic larynx treated with surgery and/or radiation therapy. Int J Radiat Oncol Biol Phys. 1984, 18: 24-35.
3.
go back to reference Kirchner JA, Owen JR: Five hundred cancers of the larynx and the pyriform sinus. Results of treatment by radiation and surgery. Laryngoscope. 1977, 87: 1288-1303. 10.1288/00005537-197708000-00009.CrossRefPubMed Kirchner JA, Owen JR: Five hundred cancers of the larynx and the pyriform sinus. Results of treatment by radiation and surgery. Laryngoscope. 1977, 87: 1288-1303. 10.1288/00005537-197708000-00009.CrossRefPubMed
4.
go back to reference VA Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991, 324 (13): 1685-90. VA Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991, 324 (13): 1685-90.
5.
go back to reference Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996, 88: 890-99. 10.1093/jnci/88.13.890.CrossRefPubMed Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996, 88: 890-99. 10.1093/jnci/88.13.890.CrossRefPubMed
6.
go back to reference Altundag O, Gullu I, Altundag K, Yalcin S, Ozyar E, Cengiz M, Akyol F, Yucel T, Hosal S, Sozeri B: Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck. 2005, 27: 15-21. 10.1002/hed.20107.CrossRefPubMed Altundag O, Gullu I, Altundag K, Yalcin S, Ozyar E, Cengiz M, Akyol F, Yucel T, Hosal S, Sozeri B: Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck. 2005, 27: 15-21. 10.1002/hed.20107.CrossRefPubMed
7.
go back to reference Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE: Organ Preservation for AdvancedResectable Cancer of the Base of Tongue and Hypopharynx: A Southwest Oncology Group Trial. J Clin Oncol. 2005, 23: 88-95. 10.1200/JCO.2005.04.017.CrossRefPubMed Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE: Organ Preservation for AdvancedResectable Cancer of the Base of Tongue and Hypopharynx: A Southwest Oncology Group Trial. J Clin Oncol. 2005, 23: 88-95. 10.1200/JCO.2005.04.017.CrossRefPubMed
8.
go back to reference Zelefsky MJ, Kraus DH, Pfister DG, Raben A, Shah JP, Strong EW, Spiro RH, Bosl GJ, Harrison LB: Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head and Neck. 1996, 18: 405-11. 10.1002/(SICI)1097-0347(199609/10)18:5<405::AID-HED3>3.0.CO;2-9.CrossRefPubMed Zelefsky MJ, Kraus DH, Pfister DG, Raben A, Shah JP, Strong EW, Spiro RH, Bosl GJ, Harrison LB: Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head and Neck. 1996, 18: 405-11. 10.1002/(SICI)1097-0347(199609/10)18:5<405::AID-HED3>3.0.CO;2-9.CrossRefPubMed
9.
go back to reference Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003, 349: 2091-8. 10.1056/NEJMoa031317.CrossRefPubMed Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003, 349: 2091-8. 10.1056/NEJMoa031317.CrossRefPubMed
10.
go back to reference Nishimura G, Tsukuda M, Horiuchi C, Satake K, Yoshida T, Nagao J, Kawakami M, Kondo N, Arai Y, Taguchi T, Matsuda H, Mikami Y: Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas. Auris Nasus Larynx. 2007, 34: 499-504. 10.1016/j.anl.2007.02.004.CrossRefPubMed Nishimura G, Tsukuda M, Horiuchi C, Satake K, Yoshida T, Nagao J, Kawakami M, Kondo N, Arai Y, Taguchi T, Matsuda H, Mikami Y: Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas. Auris Nasus Larynx. 2007, 34: 499-504. 10.1016/j.anl.2007.02.004.CrossRefPubMed
11.
go back to reference Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB: Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy. J Natl Cancer Inst. 2009, 101: 142-52. 10.1093/jnci/djn460.CrossRefPubMedPubMedCentral Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB: Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy. J Natl Cancer Inst. 2009, 101: 142-52. 10.1093/jnci/djn460.CrossRefPubMedPubMedCentral
12.
go back to reference Wu Q, Manning M, Schmidt-Ullrich R: The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys. 1995, 31: 1341-6.CrossRef Wu Q, Manning M, Schmidt-Ullrich R: The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys. 1995, 31: 1341-6.CrossRef
13.
go back to reference Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002, 53: 12-22. 10.1016/S0360-3016(02)02859-6.CrossRefPubMed Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002, 53: 12-22. 10.1016/S0360-3016(02)02859-6.CrossRefPubMed
14.
go back to reference Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-necksquamous cell carcinoma--the University of Iowa experience. Int JRadiat Oncol Biol Phys. 2005, 63: 410-21. 10.1016/j.ijrobp.2005.02.025.CrossRef Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-necksquamous cell carcinoma--the University of Iowa experience. Int JRadiat Oncol Biol Phys. 2005, 63: 410-21. 10.1016/j.ijrobp.2005.02.025.CrossRef
15.
go back to reference Guerrero Urbano T, Clark CH, Hansen VN, Adams EJ, A'Hern R, Miles EA, McNair H, Bidmead M, Warrington AP, Dearnaley DP, Harrington KJ, Nutting CM: A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol. 2007, 85: 36-41. 10.1016/j.radonc.2007.07.011.CrossRefPubMed Guerrero Urbano T, Clark CH, Hansen VN, Adams EJ, A'Hern R, Miles EA, McNair H, Bidmead M, Warrington AP, Dearnaley DP, Harrington KJ, Nutting CM: A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol. 2007, 85: 36-41. 10.1016/j.radonc.2007.07.011.CrossRefPubMed
16.
go back to reference Schoenfeld GO, Amdur RJ, Morris CG, Li JG, Hinerman RW, Mendenhall WM: Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008, 71: 377-85.CrossRefPubMed Schoenfeld GO, Amdur RJ, Morris CG, Li JG, Hinerman RW, Mendenhall WM: Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008, 71: 377-85.CrossRefPubMed
17.
go back to reference Tai HC, Hsieh CH, Chao KS, Liu SH, Leu YS, Chang YF, Hsiao HT, Chang YC, Huang DY, Chen YJ: Comparison of radiotherapy strategies for locally advanced hypopharyngeal cancer after resection and ileocolic flap reconstruction. Acta Otolaryngol. 2009, 129: 311-7. 10.1080/00016480802163366.CrossRefPubMed Tai HC, Hsieh CH, Chao KS, Liu SH, Leu YS, Chang YF, Hsiao HT, Chang YC, Huang DY, Chen YJ: Comparison of radiotherapy strategies for locally advanced hypopharyngeal cancer after resection and ileocolic flap reconstruction. Acta Otolaryngol. 2009, 129: 311-7. 10.1080/00016480802163366.CrossRefPubMed
18.
go back to reference Mohan R, Wu Q, Maning M, Schmidt-Ullrich R: Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys. 2000, 46: 619-30.CrossRefPubMed Mohan R, Wu Q, Maning M, Schmidt-Ullrich R: Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys. 2000, 46: 619-30.CrossRefPubMed
19.
go back to reference Cheng JCH, Chao KSC, Low D: Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer (Radiat Oncol Invest). 2001, 96: 126-31. 10.1002/ijc.1004.CrossRef Cheng JCH, Chao KSC, Low D: Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer (Radiat Oncol Invest). 2001, 96: 126-31. 10.1002/ijc.1004.CrossRef
20.
go back to reference Liu WS, Kuo HC, Lin JC, Su MC, Lee JK, Lee SPH, Chang HC, Chou MJ, Chou MC, Lee H: Assessment of salivary function change in nasopharyngeal carcinoma treated by parotid-sparing radiotherapy. Cancer J. 2006, 12: 494-500. 10.1097/00130404-200611000-00009.CrossRefPubMed Liu WS, Kuo HC, Lin JC, Su MC, Lee JK, Lee SPH, Chang HC, Chou MJ, Chou MC, Lee H: Assessment of salivary function change in nasopharyngeal carcinoma treated by parotid-sparing radiotherapy. Cancer J. 2006, 12: 494-500. 10.1097/00130404-200611000-00009.CrossRefPubMed
21.
go back to reference Studer G, Lütolf UM, Davis JB, Glanzmann C: IMRT inhypopharyngeal tumors. Strahlenther Onkol. 2006, 182: 331-35. 10.1007/s00066-006-1556-2.CrossRefPubMed Studer G, Lütolf UM, Davis JB, Glanzmann C: IMRT inhypopharyngeal tumors. Strahlenther Onkol. 2006, 182: 331-35. 10.1007/s00066-006-1556-2.CrossRefPubMed
22.
go back to reference Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG: Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2007, 69: 459-68.CrossRefPubMed Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG: Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2007, 69: 459-68.CrossRefPubMed
23.
go back to reference International Commission on Radiation Units and Measurements: ICRU Report 62: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50). 1999, Bethesda, MD: International Commission on Radiation Units and Measurements International Commission on Radiation Units and Measurements: ICRU Report 62: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50). 1999, Bethesda, MD: International Commission on Radiation Units and Measurements
24.
go back to reference Trotti A, Colevas AD, Setserb A, Ruschc V, Jaquesc D, Budachd V, Langere C, Murphyf B, Cumberling R, Colemang CN, Rubin P: CTCAE v3.0: Development of a Comprehensive Grading System for the Adverse Effects of CancerTreatment. Seminars in Radiation Oncology. 2003, 13: 176-181. 10.1016/S1053-4296(03)00031-6.CrossRefPubMed Trotti A, Colevas AD, Setserb A, Ruschc V, Jaquesc D, Budachd V, Langere C, Murphyf B, Cumberling R, Colemang CN, Rubin P: CTCAE v3.0: Development of a Comprehensive Grading System for the Adverse Effects of CancerTreatment. Seminars in Radiation Oncology. 2003, 13: 176-181. 10.1016/S1053-4296(03)00031-6.CrossRefPubMed
25.
go back to reference Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000, 355: 949-55.CrossRefPubMed Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000, 355: 949-55.CrossRefPubMed
26.
go back to reference Laranne J, Back L, Koivunen P, Pukkila M, Pulkkinen J, Grenman R: Hypopharyngeal carcinoma in Finland from 1990-1999. Eur Arch Otorhino. 2005, 262: 374-8. 10.1007/s00405-004-0847-4.CrossRef Laranne J, Back L, Koivunen P, Pukkila M, Pulkkinen J, Grenman R: Hypopharyngeal carcinoma in Finland from 1990-1999. Eur Arch Otorhino. 2005, 262: 374-8. 10.1007/s00405-004-0847-4.CrossRef
27.
go back to reference Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiot Oncol. 2003, 66: 253-62. 10.1016/S0167-8140(02)00404-8.CrossRef Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiot Oncol. 2003, 66: 253-62. 10.1016/S0167-8140(02)00404-8.CrossRef
28.
go back to reference de Arruda FF, Puri DR, Zhung J, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY: Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. Int J Radiat OncolBiol Phys. 2006, 64: 363-373. 10.1016/j.ijrobp.2005.03.006.CrossRef de Arruda FF, Puri DR, Zhung J, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY: Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. Int J Radiat OncolBiol Phys. 2006, 64: 363-373. 10.1016/j.ijrobp.2005.03.006.CrossRef
29.
go back to reference Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damenet E, Van As CJ, Marsh R, Pameijer FA, Balm AJM: Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT?. Int J Radiat Oncol Biol Phys. 2004, 60: 1425-1439.CrossRefPubMed Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damenet E, Van As CJ, Marsh R, Pameijer FA, Balm AJM: Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT?. Int J Radiat Oncol Biol Phys. 2004, 60: 1425-1439.CrossRefPubMed
30.
go back to reference Nangia S, Chufal KS, Tyagi A, Bhatnagar A, Mishra M, Ghosh D: Selective nodal irradiation for head and neck cancer using intensity-modulated radiotherapy: application of RTOG consensus guidelines in routine clinical practice. Int J Radiat Oncol Biol Phys. 2010, 76: 146-53.CrossRefPubMed Nangia S, Chufal KS, Tyagi A, Bhatnagar A, Mishra M, Ghosh D: Selective nodal irradiation for head and neck cancer using intensity-modulated radiotherapy: application of RTOG consensus guidelines in routine clinical practice. Int J Radiat Oncol Biol Phys. 2010, 76: 146-53.CrossRefPubMed
Metadata
Title
Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation
Authors
Wen-Shan Liu
Chung-Han Hsin
Ying-Hsiang Chou
Jung-Tung Liu
Ming-Fang Wu
Szu-Wen Tseng
Jong-Kang Lee
Hsien-Chun Tseng
Tzu-Hwei Wang
Mao-Chang Su
Huei Lee
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-102

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine